Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neocarzinostatin is a **macromolecular chromoprotein enediyne antitumor antibiotic** produced by Streptomyces macromomyceticus or Streptomyces carzinostaticus[1][3][5][7]. It consists of a **potent, labile enediyne chromophore** non-covalently bound to a 113-amino-acid protein, which stabilizes the chromophore and releases it at target DNA[1][3][7]. The chromophore acts by undergoing reductive activation in cells, triggering a Bergman cyclization and generating a benzenoid diradical; this leads to **sequence-selective single- and double-strand DNA breaks**, inhibiting DNA synthesis and inducing cell cycle arrest and apoptosis[1][3][5][6][7]. Neocarzinostatin has **antibiotic activity against Gram-positive bacteria** and **antitumor activity in liver cancer, leukemia, bladder cancer, and other solid tumors**, but clinical use is limited mainly to Japan due to its instability and toxicity[1][2][3][5][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on neocarzinostatin.